Kidney cancer
A study to optimize the dose of sunitinib based on blood levels of the drug and its metabolite in kidney cancer
Who can joinAdults
Age18+ years
Kind of studyStudy of how care is given
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Advanced Centre for Treatment, Research and Education in CancerNavi MumbaiDirections ↗
Registry summary (technical)
A randomized controlled trial of therapeutic monitoring-based dosing strategy versus standard dosing strategy of sunitinib in metastatic renal cell carcinoma
Sponsor: Advanced Cancer for Treatment Research and Education
CTRI/2020/03/023900 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 12 Jan 2026 · read by us 5 Nov 2026